Newsroom
Discover the latest news and updates from Almirall.
Quick Links
Almirall press kit
PDF 2.4MB
Year in review 2024
PDF 2.7MB
Almirall at a glance
PDF 22.1MB
Discover the latest news and updates from Almirall.
Almirall press kit
PDF 2.4MB
Year in review 2024
PDF 2.7MB
Almirall at a glance
PDF 22.1MB
569 results
Published on 10 August 2026
Almirall has entered a collaboration and licensing agreement with Chinese company CrystalO for the discovery and development of novel small molecules in medical dermatology.
The agreement builds on Almirall’s broader innovation strategy to identify innovative local R&D programmes that complement its in-house capabilities. It also reflects the company’s continued commitment to advancing differentiated treatments in areas of high unmet medical need in dermatology through strategic partnerships and scientific collaboration.
Under the terms of the agreement, CrystalO will be responsible for candidate discovery, optimisation, IND-enabling studies and early clinical development, with the aim of delivering clinical proof of concept (POC). Almirall will hold exclusive rights outside mainland China and will lead subsequent global development, manufacturing and commercialisation activities.
Commenting on the collaboration, Karl Ziegelbauer, Chief Scientific Officer at Almirall, said: “This collaboration with CrystalO marks another important step in advancing our innovation strategy in China and further reinforces our strong R&D pipeline in medical dermatology. We look forward to the potential this discovery partnership holds for delivering meaningful benefits to patients living with skin conditions worldwide.”
Dr. Zhang Jin, Founder and Chief Executive Officer of CrystalO, added: "We are honored to enter into a strategic collaboration with Almirall, a leading company with a strong global reputation in dermatology. This collaboration is a strong recognition of CrystalO's technology platform and R&D capabilities in ion channel drug discovery. We look forward to working closely with the Almirall team, fully leveraging the strengths of both parties, accelerating the development of innovative medicines, and bringing benefits to patients worldwide as early as possible".
Published on 10 August 2026
At Almirall, innovation begins with the curiosity, dedication and expertise of our teams. Every day, scientists, researchers and multidisciplinary experts work together to advance the understanding of skin diseases and address some of the most complex challenges in medical dermatology.
Driven by a deep commitment to science and a strong focus on patients’ needs, our teams combine research, collaboration and innovation to help transform insights into meaningful progress. This approach enables us to continue expanding knowledge of skin diseases and exploring new solutions that can make a difference in patients’ lives.
With a pipeline exclusively focused on medical dermatology, we are dedicated to advancing skin science and supporting continuous innovation in areas where significant unmet needs remain. Our work is guided not only by scientific excellence, but also by a determination to better understand the experiences of people living with skin conditions and the broader impact these diseases can have on their wellbeing.
Because behind every condition there is a person, our approach goes beyond the science itself. By bringing together scientific expertise, long-term ambition and a patient-centred mindset, we strive to contribute to better care and outcomes for those affected by skin diseases.
Through curiosity, collaboration and innovation, Almirall continues to advance medical dermatology with one clear purpose: helping improve patients’ lives and shaping a healthier future through science.
Published on 3 August 2026
At Almirall, our purpose is to help patients realize their hopes and dreams for a healthy life. This commitment guides everything we do, from advancing scientific knowledge in medical dermatology to fostering meaningful collaboration with healthcare professionals and patient communities around the world.
We recognize that skin diseases can have an impact far beyond physical symptoms, often affecting emotional, social and psychological well-being. Understanding this broader burden is essential to developing solutions that address the real needs of people living with skin conditions and help improve their quality of life.
Through our dedication to medical dermatology, we work to bring science closer to patients and healthcare professionals, transforming insights into innovation. By deepening our understanding of skin diseases and supporting scientific exchange, we aim to contribute to better care and outcomes for patients.
As a family-owned company, we take a long-term perspective, building trusted partnerships and investing in innovation that can create lasting value. Through the way
we collaborate, listen and learn, our teams bring this purpose to life every day, working alongside healthcare professionals, researchers and patient communities to advance care and support those affected by skin diseases.
By combining science, innovation and partnership, Almirall continues to pursue its purpose of transforming patients’ lives and contributing to a healthier future for generations to come.
Published on 24 July 2026
Published on 24 July 2026
Barcelona and San Mateo de Gállego (Zaragoza), Spain.
Almirall, S.A. (ALM) and Certest Biotec, S.L., through its pharmaceutical division Certest Pharma, today announced a strategic research collaboration and licensing agreement. Through the collaboration, the parties will jointly discover and clinically develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions.
The collaboration combines Certest’s integrated mRNA and Lipid Nanoparticle Platform with Almirall’s expertise in medical dermatology research and clinical development.
“The collaboration with Certest Biotec is aligned with Almirall’s innovation strategy and supports our commitment to advancing a differentiated pipeline and developing novel therapies in medical dermatology that address unmet patient needs,” said Karl Ziegelbauer, Chief Scientific Officer at Almirall.
“This collaboration marks an important milestone for Certest and further validates the strength of our integrated mRNA and lipid nanoparticle platform,” said Nelson Fernandes, CEO of Certest. “Partnering with Almirall allows us to apply our technology to indications with significant unmet medical needs while reinforcing our commitment to enabling the next generation of RNA-based medicines.”
Published on 20 July 2026
Published on 28 June 2026
As Pride Month comes to a close, we are reminded that the conversation around diversity, inclusion, and belonging should continue every day of the year. At Almirall, we believe that understanding the full patient experience means looking beyond the condition itself and recognizing the unique perspectives and identities that shape each person's journey.
To mark Pride Month, we talked to members of the LGBTQIA+ community who are living with Hidradenitis Suppurativa (HS) and are part of the HS Connect community. Through their personal reflections, Rae Adams, Destineé Spurrel, and Cassandra Stand share their experiences of identity, visibility, and living with a chronic condition.
Their stories highlight the importance of feeling seen, heard, and respected. They remind us that healthcare goes beyond physical symptoms and that supporting wellbeing requires listening to the diverse experiences of the people we serve.
At Almirall, our commitment to medical dermatology is rooted in a holistic approach to care—one that values every individual and fosters greater understanding, empathy, and inclusion. By amplifying patient voices and creating space for meaningful conversations, we can help build a more supportive future for everyone living with skin diseases.
Published on 25 June 2026
At Almirall, sustainability is a key part of how we create long-term value for patients, society, and the planet. We are proud to share that we have once again been included in the World’s Most Sustainable Companies 2026 ranking, compiled by TIME and Statista.
This year, we further strengthened our sustainability performance, improving our overall score from 65.8 to 72.2. This achievement reflects the steady progress we have made in implementing our sustainability strategy and embedding environmental, social, and governance principles across our business.
This recognition highlights the positive momentum of our Act4Impact strategy and the commitment of our teams to advancing responsible and sustainable practices throughout the organization. It also reinforces our belief that business success and sustainable growth go hand in hand.
As we continue our journey, we remain focused on creating a lasting positive impact—driving innovation in medical dermatology while contributing to a healthier and more sustainable future for all.
Thank you to everyone contributing to making sustainability a fundamental part of who we are and how we operate.
Published on 10 June 2026
Acne is one of the most common skin conditions worldwide, affecting millions of people across all ages and backgrounds. Yet, its impact extends far beyond the visible symptoms, often influencing self-confidence, emotional well-being, and daily life.
During Acne Awareness Month, we want to recognize the profound effect that acne and other dermatological conditions can have on those living with them. Behind every diagnosis is a unique personal journey, reminding us that skin health is about much more than what can be seen on the surface.
At Almirall, we are committed to advancing medical dermatology and deepening the scientific understanding of skin diseases. Equally important, we believe in listening to the real experiences of patients to help foster a more holistic approach to care—one that considers both physical and emotional wellbeing.
By increasing awareness and supporting the dermatology community, we aim to contribute to a future where people living with skin conditions feel understood, supported, and empowered throughout their journey.
Learn more about our commitment to holistic skin health and patient-centered care at:
https://www.almirall.com/patients
Published on 5 June 2026
At Almirall, improving the lives of patients goes hand in hand with protecting the environment we all share. This World Environment Day, we want to reinforce our commitment to taking decisive climate action on our path to becoming a net-zero emissions company by 2050.
But 2050 is built on the choices we make today. We are already making tangible progress through real, measurable actions. Our operational sites across Spain and Germany have been running on 100% renewable electricity since 2018, and in 2025 we reduced our direct greenhouse gas emissions by 22%, keeping us firmly on track to achieve our 50% reduction target by 2030.
We are also strengthening our approach to water management, having already reduced our consumption by 20% from our baseline, with the ambition to reach a 25% reduction by 2030. These efforts are helping us build greater resilience in the face of climate-related risks.
Our progress has been externally recognised, with Almirall named among Europe’s Climate Leaders 2026 by the Financial Times and Statista for the third consecutive year.
Every action we take brings us one step closer to a more sustainable future — for our patients, our communities and the planet we all share.
